Skip to main content
4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc. — Investor Relations & Filings

Ticker · FDMT ISIN · US35104E1001 US Manufacturing
Open in API
Filings indexed 372 across all filing types
Latest filing 2022-05-12 Interim / Quarterly Rep…
Country US United States of America
Listing US FDMT

About 4D Molecular Therapeutics, Inc.

https://4dmoleculartherapeutics.com/

4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on inventing and developing genetic medicines to treat large-market diseases with unmet medical needs. The company utilizes its proprietary Therapeutic Vector Evolution platform, which harnesses the power of directed evolution, to create customized and optimized adeno-associated virus (AAV) vectors. These engineered vectors are designed for targeted delivery and enhanced therapeutic efficacy. 4DMT's clinical pipeline is concentrated on developing transformative products for serious conditions in ophthalmology, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), and in pulmonology, including cystic fibrosis.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2022
2022-05-12 English
Regulatory Filings 2022
Regulatory Filings
2022-04-18 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter from 4D Molecular Therapeutics, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-3. It is a formal correspondence related to a securities registration process, specifically under the Securities Act of 1933. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory communication about the timing of a filing becoming effective, not the filing itself or a financial report. The document length is short (1651 characters), and it is clearly a regulatory filing or correspondence with the SEC. Therefore, it fits best under Regulatory Filings (RNS).
2022-04-13 English
DEFA14A
Regulatory Filings
2022-04-13 English
DEF 14A
Proxy Solicitation & Information Statement
2022-04-13 English
Regulatory Filings 2022
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify the document as a specific filing type. According to the rules, when a document does not neatly fit into any specific category and lacks identifiable content, the fallback classification is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable as a report or announcement. Therefore, the best classification is RNS with moderate confidence due to lack of content clarity.
2022-04-05 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.